Related Experiment Videos
Stenotrophomonas (Xanthomonas) maltophilia: a multidrug-resistant nosocomial pathogen
1College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, USA.
Abstract:
Stenotrophomonas (Xanthomonas) maltophilia is emerging as a multidrug-resistant nosocomial pathogen. In general, the organism is opportunistic, colonizing or infecting patients with predisposing risk factors such intensive care unit residence, malignancy, mechanical ventilation, and previous antibiotic exposure. It can cause a variety of infections depending on underlying patient-specific medical conditions. It is often part of multimicrobial infections, and determining its role as a pathogen is difficult. Trimethoprim-sulfamethoxazole (TMP-SMX) has traditionally been the most active agent against S. maltophilia. Other classes of antibiotics, with few exceptions, have not been effective. Synergistic antimicrobial combinations are now being investigated due to the bacteriostatic nature of TMP-SMX, and increasing reports of resistance to TMP-SMX. The combination of ticarcillin-clavulanate plus TMP-SMX appears to be the most promising regimen studied thus far.
Insights
Stenotrophomonas maltophilia is a growing multidrug-resistant threat, often infecting vulnerable patients. New synergistic antibiotic combinations, like ticarcillin-clavulanate plus trimethoprim-sulfamethoxazole, show promise against this opportunistic pathogen.
Area of Science:
- Medical Microbiology
- Infectious Diseases
- Antimicrobial Resistance
Background:
- Stenotrophomonas maltophilia is an opportunistic pathogen causing multidrug-resistant nosocomial infections.
- Risk factors include ICU stay, malignancy, mechanical ventilation, and prior antibiotic use.
- S. maltophilia can cause diverse infections, often in polymicrobial settings, complicating diagnosis.
Purpose of the Study:
- To investigate the efficacy of synergistic antimicrobial combinations against Stenotrophomonas maltophilia.
- To address the increasing reports of resistance to traditional therapies like trimethoprim-sulfamethoxazole.
- To identify promising treatment regimens for S. maltophilia infections.
Main Methods:
- Review of existing literature on S. maltophilia antimicrobial susceptibility.
- Analysis of studies evaluating synergistic antibiotic combinations.
- Focus on the combination of ticarcillin-clavulanate and trimethoprim-sulfamethoxazole.
Main Results:
- Trimethoprim-sulfamethoxazole (TMP-SMX) is traditionally the most effective agent.
- Increasing resistance to TMP-SMX necessitates alternative strategies.
- The combination of ticarcillin-clavulanate plus TMP-SMX demonstrates significant promise.
Conclusions:
- S. maltophilia poses a significant challenge due to its multidrug resistance.
- Synergistic antibiotic combinations are crucial for overcoming resistance and bacteriostatic limitations.
- Ticarcillin-clavulanate plus TMP-SMX represents a promising therapeutic option for S. maltophilia infections.